CN1319588C - 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 - Google Patents
治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 Download PDFInfo
- Publication number
- CN1319588C CN1319588C CNB2005100341454A CN200510034145A CN1319588C CN 1319588 C CN1319588 C CN 1319588C CN B2005100341454 A CNB2005100341454 A CN B2005100341454A CN 200510034145 A CN200510034145 A CN 200510034145A CN 1319588 C CN1319588 C CN 1319588C
- Authority
- CN
- China
- Prior art keywords
- medicine
- weight
- parts
- liver
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 107
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 53
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 53
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 53
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000008280 blood Substances 0.000 title description 46
- 210000004369 blood Anatomy 0.000 title description 44
- 208000019425 cirrhosis of liver Diseases 0.000 title description 4
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 16
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 11
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 10
- 206010067125 Liver injury Diseases 0.000 claims abstract description 10
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 238000007908 dry granulation Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 3
- -1 dry granulation Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 240000001972 Gardenia jasminoides Species 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 abstract 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 39
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 28
- 102000007330 LDL Lipoproteins Human genes 0.000 description 21
- 108010007622 LDL Lipoproteins Proteins 0.000 description 21
- 230000037396 body weight Effects 0.000 description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 19
- 235000009508 confectionery Nutrition 0.000 description 18
- 102000015779 HDL Lipoproteins Human genes 0.000 description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 17
- 201000005577 familial hyperlipidemia Diseases 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- 208000024172 Cardiovascular disease Diseases 0.000 description 13
- 208000026106 cerebrovascular disease Diseases 0.000 description 13
- 230000002526 effect on cardiovascular system Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000003172 expectorant agent Substances 0.000 description 9
- 230000003419 expectorant effect Effects 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 6
- 238000011047 acute toxicity test Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002040 relaxant effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940126678 chinese medicines Drugs 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 108700022737 rat Fat1 Proteins 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000157835 Gardenia Species 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 2
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229930188824 alisol Natural products 0.000 description 2
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- MDZKJHQSJHYOHJ-RMUAHEEJSA-N 2alpha,3beta-Dihydroxyolean-12-en-28-oic acid Natural products C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-RMUAHEEJSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- WQBCAASPALGAKX-UHFFFAOYSA-N Benzenemethanol, 4-(dimethylamino)- Chemical compound CN(C)C1=CC=C(CO)C=C1 WQBCAASPALGAKX-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OGPMEHXDIDDMDJ-UHFFFAOYSA-N Erythroglancin Natural products COc1cc(O)c2C(=O)c3c(O)cc(OC)c(O)c3C(=O)c2c1 OGPMEHXDIDDMDJ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000522641 Senna Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Chemical class 0.000 description 1
- 229920001864 tannin Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Abstract
Description
组别 | TH(mmol/L) | TG(mmol/L) |
对照组东宝肝泰组甘舒高剂量组甘舒中剂量组甘舒低剂量组 | 1.68±0.221.66±0.321.34±0.50*1.57±0.431.69±0.28 | 1.25±0.480.89±0.33*0.54±0.44**0.68±0.35**0.87±0.31* |
组别 | TC(mmol/L) | TG(mmol/L) | HDL(mmol/L) | LDL(mmol/L) |
对照组模型组东宝肝泰组甘舒高剂量组甘舒中剂量组甘舒低剂量组 | 1.63±0.25**2.89±0.342.70±0.462.54±0.43*2.77±0.472.80±0.45 | 1.25±0.42**2.38±0.241.21±0.39**0.91±0.35**1.18±0.37**1.27±0.38** | 0.78±0.230.86±0.311.02±0.31*1.26±0.301.12±0.36*0.98±0.21 | 0.36±0.13**0.87±0.210.58±0.20*0.42±0.22**0.49±0.19*0.59±0.18* |
组别 | TC(mmol/g) | TG(mmol/g) |
对照组模型组东宝肝泰组甘舒高剂量组甘舒中剂量组甘舒低剂量组 | 1.23±0.22**2.67±0.291.32±0.34**1.18±0.31**1.34±0.28**1.48±0.26** | 0.95±0.18**1.58±0.201.48±0.211.01±0.18*1.17±0.24*1.46±0.27 |
组别 | 给药前 | 1W | 3W | 5W | 7W | 9W | 11W | 13W |
对照组高剂量组中剂量组低剂量组 | 102.32±4.67101.76±6.03103.01±4.66102.78±5.23 | 115.89±8.00116.21±7.24118.43±7.54117.32±8.32 | 165.43±10.88165.82±10.11164.32±10.02166.76±12.14 | 197.48±17.87201.43±14.65199.65±14.56200.98±16.44 | 260.86±25.31264.75±25.86260.76±22.18266.33±26.53 | 304.41±32.42309.57±34.43308.65±30.67311.34±36.76 | 361.21±34.82368.76±36.17363.68±33.45372.03±37.12 | 382.43±35.38391.74±36.25386.32±35.28393.57±37.55 |
组别 | Hb(g/L) | RBC(×1012/L) | Rct(%) | PLT(×109/L) | WBC(×109/L) | WDC(%) | |||
N | L | E | M | ||||||
对照组高剂量组中剂量组低剂量组 | 136.65±6.70137.35±6.46138.43±6.32135.54±7.18 | 7.26±0.768.08±1.197.63±0.817.27±0.86 | 2.69±1.672.76±1.862.58±1.772.45±1.26 | 595.47±73.22610.00±83.35599.67±73.32590.46±71.38 | 11.34±2.8612.36±3.0312.47±2.7811.90±3.43 | 24.57±3.3625.62±3.9125.25±3.6525.12±3.47 | 78.21±8.6876.35±8.9977.46±8.2178.43±8.51 | 0.92±0.310.99±0.361.02±0.380.89±0.29 | 0.89±0.370.89±0.410.98±0.460.78±O.31 |
组别 | Hb(g/L) | RBC(×1012/L) | Rct(%) | PLT(×109/L) | WBC(×109/L) | WDC(%) | |||
N | L | E | M | ||||||
对照组高剂量组中剂量组低剂量组 | 132.45±6.28137.65±7.54132.54±6.65131.32±7.43 | 6.77±0.877.88±1.287.27±0.986.29±1.21 | 2.01±1.762.43±2.122.21±1.542.08±1.36 | 587.65±70.98598.76±83.23578.88±78.54583.43±71.48 | 10.14±2.3411.98±2.6911.08±2.4310.01±2.87 | 21.96±3.4624.76±3.0423.98±2.9523.67±3.43 | 75.77±7.8778.67±8.3276.32±7.6574.89±6.87 | 0.87±0.871.21±0.970.96±0.890.87±0.89 | 0.76±0.650.78±0.850.76±0.810.70±0.56 |
组别 | GLu(mmol/L) | CRE(mmol/L) | BUN(mmol/L) | TC(mmol/L) | TP(g/L) | ALR(g/L) | T-BIL(mmol/L) | ALT(IU/L) | AST(IU/L) | |
对照组高剂量组中剂量组低剂量组 | 6.56±0.646.78±0.626.91±0.547.12±0.73 | 64.71±7.4665.68±7.3265.35±6.4267.21±7.58 | 6.98±0.437.82±0.787.43±0.677.44±0.57 | 2.04±0921.69±0.751.86±0.691.98±0.63 | 69.61±5.0772.47±5.8173.31±5.4475.37±5.56 | 31.71±3.2334.19±3.8236.55±4.31 | 33.28±3.4513.85±4.2315.05±4.1715.52±4.36 | 13.58±4.1562.79±12.2365.48±13.2968.17±14.27 | 64.49±13.05153.57±28.28150.83±27.74157.22±29.03 | 146.13±26.16 |
组别 | GLu(mmol/L) | CRE(mmol/L) | BUN(mmol/L) | TC(mmol/L) | TP(g/L) | ALR(g/L) | T-BIL(mmol/L) | ALT(IU/L) | AST(IU/L) |
对照组高剂量组中剂量组低剂量组 | 6.47±0.627.32±0.717.47±0.827.16±0.61 | 62.43±6.5865.17±6.2464.27±6.3467.23±6.87 | 6.45±0.627.13±0.477.36±0.527.38±0.63 | 1.77±0.661.84±0.381.39±0.441.63±0.48 | 68.37±4.7371.36±5.3770.33±5.1172.28±5.78 | 30.75±3.3531.43±3.2635.21±3.3634.27±4.12 | 11.83±4.3813.07±4.2113.66±4.3215.14±4.25 | 62.86±11.7262.29±11.5465.81±13.1564.58±14.31 | 149.38±27.31150.26±28.27149.76±27.52153.33±28.26 |
组别 | 脑 | 心 | 肝 | 脾 | 肺 | 肾 |
对照组高剂量组中剂量组低剂量组 | 1.83±0.121.81±0.091.90±0.091.82±0.08 | 1.40±0.271.42±0.331.38±0.231.39±0.18 | 14.87±3.2514.37±3.2814.23±2.5815.26±3.14 | 1.70±0.551.69±0.321.66±0.511.72±0.62 | 2.86±0.612.97±0.652.81±0.702.77±0.63 | 1.50±0.291.51±0.341.49±0.271.47±0.24 |
组别 | 脑 | 心 | 肝 | 脾 | 肺 | 肾 |
对照组高剂量组中剂量组低剂量组 | 1.90±0.101.87±0.111.88±0.131.91±0.14 | 1.49±0.481.50±0.571.48±0.521.55±0.64 | 15.33±3.4315.17±3.3214.26±3.2416.18±3.36 | 1.78±0.451.82±0.421.80±0.511.84±0.53 | 2.96±0.722.85±0.672.88±0.702.72±0.58 | 1.50±0.441.48±0.411.47±0.401.57±0.51 |
组别 | 病例数 | 临床痊愈 | 有效 | 无效 | 总有效率 |
治疗组对照组 | 8040 | 56(70)24(60) | 21(26.25)10(25 ) | 3(3.75)6(15) | 77(96.25)34(85) |
症状 | 病例数 | 消失 | 好转 | 无效 | 总有效率 |
胁胀胁痛腹胀头晕乏力口苦 | 655352606340 | 52(80)44(83.02)46(88.46)41(68.33)38(60.32)24(60) | 11(16.92)8(15.09)5(9.62)12(20)15(23.81)12(25) | 2(3.08)1(1.89)1(1.92)7(11.67)10(15.87)4(15) | 63(96.92)52(98.11)51(98.08)53(88.33)53(74.13)34(85) |
组别 | 病例数 | TC | TG | HDL | LDL |
治疗组 治疗前治疗后对照组 治疗前治疗后 | 80804040 | 6.56±0.745.62±1.23**Δ6.63±0.645.97±1.15* | 2.03±1.081.36±0.86**Δ2.06±1.111.63±0.73 | 1.79±0.721.98±0.68*1.78±0.531.88±0.91 | 3.78±0.793.02±0.88*3.67±0.833.31±0.67 |
组别 | 病例数 | 治疗前不正常例数 | 治疗后转正常例数 | 转常率(%) |
治疗组对照组 | 8040 | 7032 | 5925 | 84.2978.13 |
组别 | 病例数 | 治疗前不正常例数 | 治疗后转正常例数 | 转常率(%) |
治疗组对照组 | 8040 | 8040 | 4910 | 61.2525.00 |
组别 | 病例数 | 体重(kg) | 肥胖度(%) | 肥胖指数 |
治疗组 治疗前治疗后对照组 治疗前治疗后 | 80804040 | 87.76±8.7981.54±8.42*Δ88.23±8.4586.76±8.62 | 48.43±8.6541.32±8.56*Δ47.55±7.8345.86±8.14 | 30.13±2.0929.06±1.81*Δ31.01±2.1430.86±1.78 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100341454A CN1319588C (zh) | 2005-04-18 | 2005-04-18 | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100341454A CN1319588C (zh) | 2005-04-18 | 2005-04-18 | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686273A CN1686273A (zh) | 2005-10-26 |
CN1319588C true CN1319588C (zh) | 2007-06-06 |
Family
ID=35304315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100341454A Active CN1319588C (zh) | 2005-04-18 | 2005-04-18 | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1319588C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028392B (zh) * | 2007-04-16 | 2010-05-19 | 北京艺信堂医药研究所 | 一种治疗高脂血症的中成药 |
CN105231198A (zh) * | 2015-09-16 | 2016-01-13 | 安徽阜南常晖食品有限公司 | 一种解酒护肝甜橙饮料 |
CN105853626A (zh) * | 2016-05-24 | 2016-08-17 | 内蒙古中安类风湿骨关节病专科医院有限责任公司 | 一种治疗脂肪肝、高血脂的中药组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440804A (zh) * | 2003-03-31 | 2003-09-10 | 江西汇仁药业有限公司 | 一种降血脂的中药 |
CN1593570A (zh) * | 2004-06-30 | 2005-03-16 | 曹琼 | 一种降脂的中药 |
-
2005
- 2005-04-18 CN CNB2005100341454A patent/CN1319588C/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440804A (zh) * | 2003-03-31 | 2003-09-10 | 江西汇仁药业有限公司 | 一种降血脂的中药 |
CN1593570A (zh) * | 2004-06-30 | 2005-03-16 | 曹琼 | 一种降脂的中药 |
Non-Patent Citations (1)
Title |
---|
中医药治疗脂肪肝的研究概况 张艳华,时珍国医国药,第16卷第3期 2005 * |
Also Published As
Publication number | Publication date |
---|---|
CN1686273A (zh) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100337662C (zh) | 一种治疗高血脂症的药物组合物及其制备方法 | |
CN1839996A (zh) | 一种治疗慢性肝病的中药复方制剂及其制备方法 | |
CN1348380A (zh) | 草药组合物及由其制备的抵抗ii型糖尿病的药物 | |
CN1263494C (zh) | 一种治疗产后缺乳的颗粒剂及其制备方法 | |
CN1565583A (zh) | 治疗糖尿病及其并发症的中药组合物 | |
CN1255138C (zh) | 一种对酒精性肝损伤具有辅助保护作用的中药制剂及制备方法 | |
CN1618446A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1319588C (zh) | 治疗高血脂、脂肪肝、肝纤维化的药物和制备方法 | |
CN1191082C (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1917895A (zh) | 鱼腥草和插田泡的提取物及其用于预防和治疗过敏性疾病的组合物 | |
CN1557842A (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
CA2976896C (en) | Water extracts of cinnamon and radix astragali | |
CN101036722A (zh) | 一种缓解疲劳、改善男性更年期综合征的保健食品及制备 | |
CN1297290C (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1899536A (zh) | 一种治疗糖尿病肾病的药物及其制备方法 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1284570C (zh) | 一种治疗高血脂症的中药制剂及其制备方法 | |
CN1290529C (zh) | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 | |
CN1548138A (zh) | 一种治疗虚损病的中药组合物及其质量控制方法 | |
CN1733089A (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1899415A (zh) | 一种治疗慢性肝病的中药复方制剂及其制备方法 | |
CN1331466C (zh) | 一种治疗肝胆疾病的药物制剂及其制备方法 | |
CN1194743C (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法和质量控制方法 | |
CN100349530C (zh) | 一种具有抗疲劳和抗氧化功能的保健品及制备方法 | |
CN1723801A (zh) | 一种具有通便美容功能的保健品及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU LANYUN MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG JING Effective date: 20100831 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 ROOM 601, NO.15, HUAJING ROAD, ZHONGSHAN AVENUE, TIANHE DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 D909, INTERNATIONAL BUSINESS INCUBATOR ZONE D, NO.3, JUQUAN ROAD, SCIENCE CITY OF HIGH-TECH INDUSTRIAL DEVELOPMENT AREA, GUANGZHOU |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100831 Address after: 510663 high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee after: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. Address before: 510630 Guangdong city of Guangzhou province Tianhe District Zhongshan Road No. 15, Room 601, Hua Jing Lu Patentee before: Zhang Jing |
|
DD01 | Delivery of document by public notice |
Addressee: Zhang Jing Document name: Notification of Passing Examination on Formalities |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 510663 Guangdong city of Guangzhou province high tech Industrial Development Zone of Guangzhou Science City skim Springs Road No. 3, Guangzhou international business incubator B District 301 Patentee after: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. Address before: Guangzhou hi tech Industrial Development Zone, Science City skim Springs Road No. 3, Guangzhou international business incubator D D909 Patentee before: GUANGZHOU LANYUN MEDICINE RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230710 Address after: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee after: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. Address before: 510663 No.301, zone B, Guangzhou International Business Incubator, No.3, Juquan Road, Science City, Guangzhou high tech Industrial Development Zone, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU HONGYUN MEDICAL SCIENTIFIC AND TECHNOLOGICAL CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Building D, 2nd Floor, No. 1168 Huanli Road, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen City, Guangdong Province, 518107 Patentee after: Hongtai (Shenzhen) Pharmaceutical Technology Co.,Ltd. Address before: 519000 Card slot 05, Room 408, Building 21, No. 1889 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee before: Zhuhai Hengqin Hongtai Pharmaceutical Technology Co.,Ltd. |